Back to search results

Berobenatide (PF-08653944) for Overweight or Obesity

This study is looking into a medicine called berobenatide (PF-08653944) to see if it can help people who are overweight or have obesity lose weight. Some participants may also have type 2 diabetes. About 950 adults will join this study. You would receive either berobenatide or a placebo (a shot with no medicine) given under the skin. The main goal is to see how much your body weight changes over 72 weeks (about 1.5 years). To join, you need to be at least 18 years old and have a certain Body Mass Index (BMI). If your BMI is between 27 and 30, you also need to have at least one weight-related health issue like high blood pressure or sleep apnea. The study is currently recruiting participants.

Study design
This study compares berobenatide to a placebo, involving about 950 adult participants. It is an interventional study, meaning participants will receive a specific treatment.
What's involved
You would participate in this study for about 20 months, with approximately 15 visits to the study site.
Compensation
Not stated in the trial record.
Follow-up
Your body weight will be measured at the beginning of the study and again at Week 72.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07595549

A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity

Recruiting
PHASE3Ages 18+InterventionalTreatment
Pfizer
~954 participants
Updated 2026-08-17 on ClinicalTrials.gov
What's tested:PF-08653944Placebo

At a glance

Recruiting sites
30 of 38 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Percent change from baseline in body weight
Measured over Baseline, Week 72

Conditions

Obesity
Overweight and/or Obesity
Overweight

Explore related trials

ObesityOverweightType 2 Diabetes Mellitus

Where it's being run

38 sites across 18 states
California8
Florida6
Tokyo4
North Carolina3
Ontario3
Ohio2
Illinois1
Indiana1

Study leadership

  • Pfizer CT.gov Call Center · STUDY_DIRECTOR · Pfizer

Who to contact

Pfizer CT.gov Call Center
[email protected]
1-800-718-1021
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Aged ≥18 years.
BMI of: ≥30 kg/m2 or ≥27.0 kg/m2 to \<30.0 kg/m2 and must have at least 1 of the following weight-related co-morbidities: hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease, or T2D.

Exclusion

Have a self-reported body weight change greater than 5% within 90 days prior to Screening.
Diagnosis of type 1 diabetes or any other form of diabetes other than T2D.
History of acute or chronic pancreatitis.
Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN-2).

What this trial measures

  • Percent change from baseline in body weightBaseline, Week 72